The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice

Experimental Neurology
Stefan LorenzlM Flint Beal

Abstract

In amyotrophic lateral sclerosis (ALS), there is increased expression of matrix metalloproteinases (MMPs) and degradation of the extracellular matrix in postmortem spinal cord tissue. We used zymography and in situ zymography to analyze the expression of MMP-2 and MMP-9 in spinal cord tissue from the G93A transgenic mouse model of ALS. Expression of MMP-9 was increased in the spinal cord of G93A mice. For functional analysis of the role of MMPs, we investigated the effects of oral administration of the MMP inhibitor Ro 28-2653 (100 mg/kg), starting at the age of 30 days (n = 19) and on disease onset (starting at the age of 90 days (n = 10)). Treatment with the MMP inhibitor Ro 28-2653 starting at 30 days of age improved motor performance and significantly (P < 0.05) prolonged the survival time of the animals (136 +/- 12 versus 123 +/- 12 days, mean +/- SD), however, administration at disease onset did not significantly improve survival time. Our experiments show that MMPs are expressed in an animal model of ALS and may play a role in the complex pathophysiologic changes. Early pharmacologic inhibition with a synthetic MMP inhibitor extends survival of the animals which suggest a role of MMPs in the early phase of the disease.

References

Dec 16, 1998·Journal of the Neurological Sciences·S OnoM Yamauchi
Dec 29, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M AsahiE H Lo
Jul 4, 2001·Nature Reviews. Neuroscience·V W YongD R Edwards
Feb 19, 2002·Neurochemistry International·Fiona M MenziesPamela J Shaw
Jun 7, 2002·The Journal of Biological Chemistry·Marina MattiazziGiovanni Manfredi
Apr 12, 2003·Neurochemistry International·Stefan LorenzlM Flint Beal
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik MaquoiAgnès Noël
Aug 12, 2004·Free Radical Biology & Medicine·Kristin K Nelson, J Andres Melendez
Feb 22, 2005·Biochemical and Biophysical Research Communications·Diego DemeulemeesterH Roger Lijnen
Mar 11, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Chetan VijayvergiyaGiovanni Manfredi
Jul 8, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Zezong GuStuart A Lipton

❮ Previous
Next ❯

Citations

Jan 22, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Patrizia BossolascoVincenzo Silani
Mar 17, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Stefan Lorenzl
Jun 1, 2011·Acta Neuropathologica·Grazia DevigiliClaudia Sommer
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·V Wee YongDavid P Stirling
Oct 3, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·I Niebroj-DoboszH Kwiecinski
Apr 11, 2013·Molecular Brain·Khanh vinh quốc Long, Lan Thi Hoàng Nguyễn
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Stefano ZoccolellaPaolo Lamberti
Jul 3, 2007·Expert Opinion on Emerging Drugs·Richard S BedlackMerit E Cudkowicz
Aug 6, 2011·Progress in Neurobiology·Giulietta RiboldiStefania Corti
Dec 3, 2015·Surgical Neurology International·Sara ZareiAngel Chinea
Aug 14, 2012·Neurobiology of Disease·Hala S Alameddine
Apr 4, 2013·Critical Reviews in Biochemistry and Molecular Biology·Jennifer VandoorenGhislain Opdenakker
Jun 7, 2014·Frontiers in Cellular Neuroscience·Dora Brites, Ana R Vaz
Jun 16, 2009·Journal of the Neurological Sciences·Lubin FangJohannes Brettschneider
Jan 28, 2014·Neuron·Artem KaplanChristopher E Henderson
Jan 21, 2012·European Neurology·Fredrik RomiNils Erik Gilhus
Apr 6, 2007·Muscle & Nerve·Susanne Renaud, David Leppert
Aug 12, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Fares BassilPierre-Olivier Fernagut
Feb 22, 2011·Journal of Neuroscience Research·Kazunori MiyazakiKoji Abe
Jan 14, 2017·Frontiers in Molecular Neuroscience·Maria-Letizia CampanariEdor Kabashi
Jun 15, 2019·Cellular and Molecular Life Sciences : CMLS·Santiago RiveraKévin Baranger
Jan 1, 2013·Journal of Neurodegenerative Diseases·Julianne AebischerCédric Raoul
Apr 15, 2017·Acta Neuropathologica·Jik NijssenEva Hedlund
Jul 31, 2010·Neuron·Ashu Johri, M Flint Beal

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.